KRAS and pancreatic ductal adenocarcinoma: The hotspot mutations (G12, G13, and Q61) of KRAS, overcomes the GTPase activity and promote the proliferation & progression of various cancers including pancreatic ductal adenocarcinoma (PDAC), colorectal adenocarcinoma (CRC), and non-small cell lung cancer (NSCLC) respectively [49, 50].